The Selective Syk Inhibitor P505-15 (PRT062607) Inhibits B Cell Signaling and Function In Vitro and In Vivo and Augments the Activity of Fludarabine in Chronic Lymphocytic Leukemia

類似資料

• PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers
  著者:: Coffey, Greg, 等
  出版事項: (2016)
• PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model
  著者:: Reilly, Michael P., 等
  出版事項: (2011)
• A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor
  著者:: Burke, Russell T, 等
  出版事項: (2014)
• Critical role for Syk in responses to vascular injury
  著者:: Andre, Patrick, 等
  出版事項: (2011)
• Selective, novel Spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B cell activation and migration
  著者:: Hoellenriegel, Julia, 等
  出版事項: (2012)